for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-U.S. CMS Says Takes Steps To Ensure Medicare Beneficiaries Have Wide Access To COVID-19 Antibody Treatment

Nov 10 (Reuters) - U.S. CMS:

* TAKES STEPS TO ENSURE MEDICARE BENEFICIARIES HAVE WIDE ACCESS TO COVID-19 ANTIBODY TREATMENT

* MEDICARE BENEFICIARIES CAN NOW RECEIVE COVERAGE OF MONOCLONAL ANTIBODIES TO TREAT COVID-19 WITH NO COST-SHARING IN PUBLIC HEALTH EMERGENCY

* CMS’ COVERAGE OF MONOCLONAL ANTIBODY INFUSIONS APPLIES TO BAMLANIVIMAB, WHICH RECEIVED AN EMERGENCY USE AUTHORIZATION FROM FDA

* ANTICIPATES THAT MONOCLONAL ANTIBODY PRODUCT WILL INITIALLY BE GIVEN TO HEALTH CARE PROVIDERS AT NO CHARGE

* MEDICARE TO NOT PAY FOR MONOCLONAL ANTIBODY PRODUCTS THAT PROVIDERS RECEIVE FREE

* LATEST ACTION PROVIDES FOR REIMBURSEMENT FOR INFUSION OF PRODUCT Source: go.cms.gov/3lxr6NL

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up